Evidence map›Paper›PMID 34604416›Full record

ArticleReports of biochemistry & molecular biology2021

Highlighting Levels of Indoxyl Sulphate among Critically Ill Patients with Acute Nephrotoxicity; Correlations Between Indoxyl Sulphate Levels and Patients' Characteristics.

Nermien Yousef Selim, Hazem Farag Mannaa, Ola Atef Sharaki, Tayseer Zaytoun, Noha Elkholy, Waleed Arafat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reports of biochemistry & molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nermien Yousef SelimMedical Research Center, Faculty of Medicine, University of Alexandria, Egypt.
Hazem Farag MannaaMedical Biochemistry Department, Faculty of Medicine, University of Alexandria, Egypt.
Ola Atef SharakiClinical Pathology Department, Faculty of Medicine, University of Alexandria, Egypt.
Tayseer ZaytounCritical Care Medicine center, Faculty of Medicine, University of Alexandria, Egypt.
Noha ElkholyNephrology Department, Faculty of Medicine, University of Alexandria, Egypt.
Waleed ArafatClinical Oncology Department, Faculty of Medicine, University of Alexandria, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany animal studies suggested that the uremic toxin indoxyl sulphate can add to renal damage following induced nephrotoxicity and this effect has not been proved in patients with such complication.

methodsThis is a prospective, case-control, and an observational study conducted on 74 critically ill patients with acute nephrotoxicity. It was designed to measure serum levels of indoxyl sulphate on the day of enrollment and over the course of their illness using high performance liquid chromatography (HPLC-UV) and to test the correlation between these levels and patient's demographics, clinical characteristics, physiological variables, and their outcomes.

resultsCritically ill patients with acute nephrotoxicity had significantly higher total (

conclusionSerum indoxyl sulphate levels were elevated in critically ill patients with acute nephrotoxicity. There is an association between high levels of indoxyl sulphate and no renal-recovery outcome among survivors of acute nephrotoxicity. Early removal of indoxyl sulphate from patients' blood may improve their outcomes.

Indexed as

HPLCIndoxyl sulphateMortalityPrognosisToxic acute kidney injury

Identifiers

PMID34604416
PMCPMC8480295
OpenAlexW3201092362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.